RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Update

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 1,671,500 shares, a decrease of 33.1% from the March 31st total of 2,497,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

RemeGen Stock Performance

Shares of OTCMKTS:REGMF remained flat at $2.09 on Monday. The stock has a fifty day moving average price of $2.09 and a two-hundred day moving average price of $3.13. RemeGen has a 1 year low of $2.01 and a 1 year high of $4.10.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.